Cargando…

Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities

Bone remodeling, a dynamic process in which bone formation by osteoblast is preceded by bone resorption by osteoclast, is a vital physiological process for maintaining bone mass and strength, imbalances in which could precipitate osteoporosis. Due to the unilateral mechanism of the existing bone rem...

Descripción completa

Detalles Bibliográficos
Autores principales: Imtiyaz, Zuha, Lin, Yi-Tzu, Liang, Fang-Yu, Chiou, Wen-Fei, Lee, Mei-Hsien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327267/
https://www.ncbi.nlm.nih.gov/pubmed/34349644
http://dx.doi.org/10.3389/fphar.2021.670254
_version_ 1783732040438382592
author Imtiyaz, Zuha
Lin, Yi-Tzu
Liang, Fang-Yu
Chiou, Wen-Fei
Lee, Mei-Hsien
author_facet Imtiyaz, Zuha
Lin, Yi-Tzu
Liang, Fang-Yu
Chiou, Wen-Fei
Lee, Mei-Hsien
author_sort Imtiyaz, Zuha
collection PubMed
description Bone remodeling, a dynamic process in which bone formation by osteoblast is preceded by bone resorption by osteoclast, is a vital physiological process for maintaining bone mass and strength, imbalances in which could precipitate osteoporosis. Due to the unilateral mechanism of the existing bone remodeling drugs, identifying compounds that could regulate the balance between osteoclast and osteoblast could improve the treatment of osteoporosis. Here, we show that compounds isolated from Wikstroemia taiwanensis modulate osteoclast and osteoblast activities. Specifically, astragalin (1) and kaempferol 3-O-β-D-apiofuranosyl-(1→6)-β-D-glucopyranoside (2), besides increasing mineral deposition, increased alkaline phosphatase activity (137.2% for 1 and 115.8% for 2) and ESR-α expression (112.8% for 1 and 122.5% for 2) in primary human osteoblasts. In contrast, compounds 1, 2, 3, and 5 inhibited tartrate-resistant acid phosphatase (TRAP) activity in receptor activator of nuclear factor-κB ligand-induced osteoclasts by 40.8, 17.1, 25.9, and 14.5% and also decreased the number of TRAP-positive cells by 51.6, 26.8, 20.5, and 18.6%, respectively. Our findings, therefore, showed that compounds isolated from W. taiwanensis could increase osteoblast activity while simultaneously decreasing osteoclast activity, and hence, warrant further evaluation for development as anti-osteoporosis agents.
format Online
Article
Text
id pubmed-8327267
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-83272672021-08-03 Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities Imtiyaz, Zuha Lin, Yi-Tzu Liang, Fang-Yu Chiou, Wen-Fei Lee, Mei-Hsien Front Pharmacol Pharmacology Bone remodeling, a dynamic process in which bone formation by osteoblast is preceded by bone resorption by osteoclast, is a vital physiological process for maintaining bone mass and strength, imbalances in which could precipitate osteoporosis. Due to the unilateral mechanism of the existing bone remodeling drugs, identifying compounds that could regulate the balance between osteoclast and osteoblast could improve the treatment of osteoporosis. Here, we show that compounds isolated from Wikstroemia taiwanensis modulate osteoclast and osteoblast activities. Specifically, astragalin (1) and kaempferol 3-O-β-D-apiofuranosyl-(1→6)-β-D-glucopyranoside (2), besides increasing mineral deposition, increased alkaline phosphatase activity (137.2% for 1 and 115.8% for 2) and ESR-α expression (112.8% for 1 and 122.5% for 2) in primary human osteoblasts. In contrast, compounds 1, 2, 3, and 5 inhibited tartrate-resistant acid phosphatase (TRAP) activity in receptor activator of nuclear factor-κB ligand-induced osteoclasts by 40.8, 17.1, 25.9, and 14.5% and also decreased the number of TRAP-positive cells by 51.6, 26.8, 20.5, and 18.6%, respectively. Our findings, therefore, showed that compounds isolated from W. taiwanensis could increase osteoblast activity while simultaneously decreasing osteoclast activity, and hence, warrant further evaluation for development as anti-osteoporosis agents. Frontiers Media S.A. 2021-07-13 /pmc/articles/PMC8327267/ /pubmed/34349644 http://dx.doi.org/10.3389/fphar.2021.670254 Text en Copyright © 2021 Imtiyaz, Lin, Liang, Chiou and Lee. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Imtiyaz, Zuha
Lin, Yi-Tzu
Liang, Fang-Yu
Chiou, Wen-Fei
Lee, Mei-Hsien
Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title_full Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title_fullStr Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title_full_unstemmed Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title_short Compounds Isolated from Wikstroemia taiwanensis Regulate Bone Remodeling by Modulating Osteoblast and Osteoclast Activities
title_sort compounds isolated from wikstroemia taiwanensis regulate bone remodeling by modulating osteoblast and osteoclast activities
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8327267/
https://www.ncbi.nlm.nih.gov/pubmed/34349644
http://dx.doi.org/10.3389/fphar.2021.670254
work_keys_str_mv AT imtiyazzuha compoundsisolatedfromwikstroemiataiwanensisregulateboneremodelingbymodulatingosteoblastandosteoclastactivities
AT linyitzu compoundsisolatedfromwikstroemiataiwanensisregulateboneremodelingbymodulatingosteoblastandosteoclastactivities
AT liangfangyu compoundsisolatedfromwikstroemiataiwanensisregulateboneremodelingbymodulatingosteoblastandosteoclastactivities
AT chiouwenfei compoundsisolatedfromwikstroemiataiwanensisregulateboneremodelingbymodulatingosteoblastandosteoclastactivities
AT leemeihsien compoundsisolatedfromwikstroemiataiwanensisregulateboneremodelingbymodulatingosteoblastandosteoclastactivities